[Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment].

Date publication

mars 2017

Journal

Bulletin du cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier , Pr FEUGIER Pierre , Pr NERICH Virginie

Tous les auteurs :
Anthony S, Hebel P, Garrel A, Oliveri V, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Delarue R, Ysebaert L, Sebban C, Broussais F, Damaj G, Nerich V, Jais JP, Salles G, Henry-Amar M, Mounier N

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28214006

Résumé

Since the introduction of targeted therapies, specific lymphoma mortality has decreased. Possible long-term toxicities, however, are not known yet. This article describes the implementation of the SIMONAL study that investigates the hypothesis of an overconsumption of care after lymphoma treatment with a 10-year follow-up.

Mots clés

Adult, Aged, Aged, 80 and over, Antineoplastic Agents, therapeutic use, Data Collection, methods, Demography, statistics & numerical data, Female, Follow-Up Studies, France, epidemiology, Health Services Needs and Demand, statistics & numerical data, Humans, Internet, Lymphoma, Non-Hodgkin, epidemiology, Male, Middle Aged, Molecular Targeted Therapy, Rituximab, therapeutic use, Surveys and Questionnaires, Time Factors

Référence

Bull Cancer. 2017 Mar;104(3):221-231